KWC Expands to Include 12 Locations by Q1 2022, Further Establishing its Position as the
Nation’s Largest Chain of Wellness Clinics, Adds to Delic’s Network of Locations

VANCOUVER, BC, Dec. 2, 2021Delic Holdings Corp (“Delic”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced its subsidiary Ketamine Wellness Centers (KWC) plans to open two new clinics in Salt Lake City, Utah, and Reno, Nevada, by February 2022. KWC was acquired by Delic in September 2021 and currently operates 10 ketamine infusion treatment clinics across eight states, delivering more than 60,000 treatments to date across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington.

KWC Salt Lake City, located in the suburb of Taylorsville at 6087 South Redwood Road, Suite B, is the first of the company’s clinics in Utah and is expected to open on January 10, 2022. The facility, which allows for up to seven treatment rooms, will become one of KWC’s largest clinics in the U.S.


  Subscribe to news from
Delic Holdings

Be the first to know when breaking news are released.



KWC Reno, opening in February 2022, will be KWC’s second clinic in Nevada and is strategically positioned to not only serve local residents but also patients in larger California markets who do not have access to affordable in-state providers.

“Offering accessible, personalized and high-quality care is integral to Ketamine Wellness Centers’ mission, and we look forward to supporting the emotional wellness of new patients in Utah and Nevada,” said Kevin Nicholson, CEO of KWC and Chief Operating Officer for Delic. “As the nation grapples with the ongoing silent mental health crisis, we are committed to helping patients struggling with various conditions get back control over their lives again and find relief through these powerful treatments.”

Through these latest openings, Delic continues to execute its strategy of expanding ketamine treatment centers to secondary cities in order to reach the greatest number of patients and provide reasonably priced treatments.

Matt Stang, co-founder and CEO of Delic, commented, “Demand for mental health services continues to climb year over year, with one in five U.S. adults experiencing a mental health condition. However, patients around the country still lack access to affordable and effective options. Through the largest chain of wellness clinics offering ketamine treatments in the U.S., Delic aims to directly address this critical issue by focusing our efforts on expanding access to these best-in-class treatments to more people every day. We believe affordable, effective treatments with minimal side effects should be available to anyone who needs them.”

In addition to the 12 KWC clinics, Delic’s existing portfolio also includes two clinics operated by Ketamine Infusion Centers LLC (“KIC”) in California and Arizona, cementing its position as the leading and largest psychedelic wellness provider in the country. Delic expects to open 13 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from new medicines and treatments for a variety of mental health conditions and adds to their position as a central hub of education, media, and cultural conversations around these new medicines and treatments.

Delic is committed to addressing the mental health crisis by increasing access to science-backed benefits for all and reframing the psychedelic conversation. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) the largest and most accessible network of physical clinics to administer effective treatments, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines, and 3) trusted media and e-commerce platforms and in-person events to market the services directly to patients and consumers and gain data.

For more information about Ketamine Wellness Centers’ locations, services and hours of operation, please visit https://www.ketaminewellnesscenters.com/locations/.

About Ketamine Wellness Centers

Ketamine Wellness Centers (KWC)Β is the largest ketamine therapy provider in the United States with 12 clinic locations serving communities across nine states. Since 2011 KWC has been a trusted leader in bringing IV ketamine therapy into mainstream health care. KWC has provided over 60,000 treatments to clinically eligible patients, from young adults to seniors, in addition to developing specialized programs for veterans and first responders. The KWC team, including a core group of physicians, psychologists, clinicians, and executives, is dedicated to providing value-based, personalized, clinically controlled ketamine infusion care for people suffering from treatment-resistant depression, anxiety, PTSD, OCD and chronic pain. KWC’s scalable business and treatment model is designed for further rapid expansion along with breakthrough innovations in effective therapies and services.

About Delic Corp

DelicΒ is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities β€Žin the United States. The securities have not been and will not be registered β€Žunder the United States β€ŽSecurities Act of 1933, as amended (the “U.S. Securities Act”), or any state β€Žsecurities laws and may not be offered or β€Žsold within the United States unless registered under the U.S. β€ŽSecurities Act and applicable state securities laws or an β€Žexemption from such registration is available.β€Ž

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable β€ŽCanadian securities β€Žlegislation and may also contain statements that may constitute “forward-looking β€Žstatements” within the meaning of β€Žthe safe harbor provisions of the United States Private Securities β€ŽLitigation Reform Act of 1995. Such forward-looking β€Žinformation and forward-looking statements are not β€Žrepresentative of historical facts or information or current β€Žcondition, but instead represent only the β€ŽCompany’s beliefs regarding future events, plans or objectives, many of β€Žwhich, by their nature, are β€Žinherently uncertain and outside of Delic’s control. Generally, such forward-looking β€Žinformation or β€Žforward-looking statements can be identified by the use of forward-looking terminology such as β€Žβ€Ž”plans”, β€Žβ€Ž”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, β€Žβ€Žβ€Ž”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may β€Žcontain β€Žstatements that certain actions, events or results “may”, “could”, “would”, “might” or “will be β€Žtaken”, “will continue”, β€Žβ€Ž”will occur” or “will be achieved”. The forward-looking information and forward-β€Žlooking statements contained herein β€Žmay include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction;Β  anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business β€Žobjectives, β€Žand expectations β€Žfor other economic, β€Žbusiness, and/or competitive factors.β€Ž

By identifying such information and statements in this manner, Delic is alerting the reader that β€Žsuch β€Žinformation and statements are subject to known and unknown risks, uncertainties and other factors β€Žthat may cause β€Žthe actual results, level of activity, performance or achievements of Delic to be β€Žmaterially different from those β€Žexpressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in connection with the forward-looking β€Žinformation and forward-looking statements contained in this press β€Žrelease, Delic has made certain β€Žassumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; β€Žthe ability of the parties to β€Žobtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of β€Žother conditions to the β€Žconsummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on β€Žrelationships, β€Žincluding with regulatory bodies, employees, suppliers, customers and competitors; β€Žchanges in general economic, β€Žbusiness and political conditions, including changes in the financial β€Žmarkets; changes in applicable laws; compliance β€Žwith extensive government regulation; and the diversion β€Žof management time on the Transaction.β€Ž

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions β€Žunderlying the β€Žforward-looking information or statements prove incorrect, actual results may vary β€Žmaterially from those described β€Žherein as intended, planned, anticipated, believed, estimated or β€Žexpected.β€Ž

Although Delic believes that the assumptions and factors used in preparing, and the expectations β€Žcontained β€Žin, the forward-looking information and statements are reasonable, undue reliance should not β€Žbe placed on such β€Žinformation and statements, and no assurance or guarantee can be given that such β€Žforward-looking information and β€Žstatements will prove to be accurate, as actual results and future events β€Žcould differ materially from those anticipated β€Žin such information and statements. The forward-looking β€Žinformation and forward-looking statements contained in this β€Žpress release are made as of the date of β€Žthis press release, and Delic does not undertake to update any β€Žforward-looking information β€Žand/or forward-looking statements that are contained or referenced herein, except in β€Žaccordance with β€Žapplicable securities laws. All subsequent written and oral forward- looking information and β€Žstatements β€Žattributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this β€Žβ€Žnotice.β€Ž

SOURCE Delic Holdings Inc.

Related Links

https://deliccorp.com/